Skip to content
Home/Companies/Biotech/HI-Bio
HB

HI-Bio

Biotech·US·Exited 2024·Held 3yr

HI-Bio is a healthcare company, headquartered in France.

Entry
2021
Hold
3yr
Exit
2024
Est. EV
–

Who owns HI-Bio?

HI-Bio was owned by Jeito Capital through Jeito I (2021 vintage) from 2021 to 2024, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Jeito Capital
Investor
Jeito Capital
Jeito I · 2021 · VC

Key facts

HQFrance
SectorHealthcare
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2024

More from Jeito I

Other portfolio companies in the same fund.

Corteria Pharmaceuticals
Active
BiotechFrance· 2023
Noema Pharma
Active
BiotechSwitzerland· 2023
Advesya
Active
BiotechSpain· 2022
CatalYm
Active
BiotechGermany· 2022
CDR-Life
Active
BiotechSwitzerland· 2022
EyeBio
Exited 2024
BiotechUS· 2022
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings